IBRANCE (palbociclib) Recommended Dose Modifications for Adverse Reactions

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.
English (USA)
Adverce Events from CTCAE: 
Anemia
Febrile neutropenia
Blood and lymphatic system disorders - Other
Blurred vision
Conjunctivitis
Dry eye
Watering eyes
Abdominal pain
Constipation
Diarrhea
Mucositis oral
Nausea
Vomiting
Gastrointestinal disorders - Other
Fatigue
Fever
Bronchial infection
Conjunctivitis infective
Corneal infection
Enterocolitis infectious
Eye infection
Laryngitis
Lung infection
Nail infection
Papulopustular rash
Paronychia
Periorbital infection
Pharyngitis
Rash pustular
Rhinitis infective
Sinusitis
Skin infection
Tooth infection
Upper respiratory infection
Urinary tract infection
Infections and infestations - Other
Alanine aminotransferase increased
Alkaline phosphatase increased
Aspartate aminotransferase increased
Blood bilirubin increased
Electrocardiogram QT corrected interval prolonged
Hemoglobin increased
Lymphocyte count decreased
Neutropenia
Thrombocytopenia
Leukopenia
Anorexia
Generalized muscle weakness
Dysgeusia
Headache
Epistaxis
Alopecia
Rash acneiform
Rash maculo-papular
Arthralgia
Arthritis
Infections
Rash
Skin and subcutaneous tissue disorders - Other
Malaise
Pneumonitis
Dry skin
Product: 
IBRANCE (en-us): IBRANCE® capsules (palbociclib)
Top block: 

This tool was designed to help you assess the grade of the adverse event reported by your patient and to get dosing modifications recommendations based on the grade of the event as per the approved IBRANCE Prescribing Information.

  • Step 1: select an adverse event (see most common adverse reactions below, please use our search functionality or switch to view the full list)
  • Step 2: assess the grade of the adverse event as per CTCAE 4.0 criteria
  • Step 3: determine appropriate dosing modifications strategies

If you need additional information (including the incidence of the adverse events occurring in the pivotal palbociclib randomized clinical trials), please consult the approved IBRANCE® capsules Prescribing Information or IBRANCE® tablets Prescribing Information, search through our collection of approved scientific response documents or contact us directly (submit a request online, or call 1-800-438-1985).

Footer block: 

The recommended dose of IBRANCE is a 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Dosing interruption and/or dose reductions for IBRANCE are recommended based on individual safety and tolerability. Please refer to the full IBRANCE® capsules Prescribing Information or IBRANCE® tablets Prescribing Information for the coadministered endocrine therapy for dosing recommendations and dose adjustment guidelines in the event of toxicity.

Pfizer is unable to make any specific dosage and/or treatment recommendations for individual patients beyond palbociclib dosage modifications as described in the IBRANCE Prescribing Information; clinical judgment based on the medical history and the clinical status of a specific patient will dictate the appropriate actions to be taken.

Most common AE: 
Neutropenia
Leukopenia
Anemia
Thrombocytopenia
Infections
Nausea
Diarrhea
Vomiting
Mucositis oral
Anorexia
Alopecia
Dry skin
Rash
Fatigue
Malaise
Fever
Recommended Dose Modifications: 
IBRANCE tool - Dose Modification – Hematologic Toxicities
IBRANCE tool - Dose Modification – Neutropenia
IBRANCE tool - Dose Modification – Non-Hematologic Toxicities